Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal bevacizumab + pemetrexed for leptomeningeal metastasis from lung adenocarcinoma
ChiCTR2500110079Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab and pemetrexed in Carcinomatous Meningitis (CM) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Adverse events and Overall survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bevacizumabpemetrexed
03
Conditions
Carcinomatous Meningitis (CM)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110079.